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Abstract Macroautophagy and chaperone-mediated autoph-
agy (CMA) are two important subtypes of autophagy that play
a critical role in cellular quality control under physiological
and pathological conditions. Despite the marked differences
between these two autophagic pathways, macroautophagy
and CMA are intimately connected with each other during
the autophagy-lysosomal degradation process, in partic-
u l a r , i n t he s e t t i ng o f neu ro log i c a l i l l n e s s .
Macroautophagy serves as a backup mechanism to re-
moval of malfunctioning proteins (i.e., aberrant α-synu-
clein) from the cytoplasm when CMA is compromised,
and vice versa. The molecular mechanisms underlying
the conversation between macroautophagy and CMA are
being clarified. Herein, we survey current overviews
concentrating on the complex interactions between
macroautophagy and CMA, and present therapeutic po-
tentials through utilization and manipulation of
macroautophagy-CMA crosstalk in the treatment of neu-
rological diseases.
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Introduction
Autophagy is an evolutionarily conserved lysosomal degra-
dation pathway by which cytoplasmic materials are delivered
to and degraded in the lysosome [1]. It is essential for cell
survival, differentiation, development, and homeostasis [2, 3].
Dysfunction of the autophagy-lysosomal pathway has been
linked to a wide variety of brain pathology such as acute brain
injuries [4, 5], neurodegenerative diseases (i.e., Alzheimer’s
(AD), Parkinson’s (PD), and Huntington’s disease (HD))
[6–8], and brain tumors [9]. It is therefore significant to
characterize the role of autophagy and its regulation in these
diseases for therapeutic purpose.
Depending on the mode of cargo delivery to lysosome,
autophagy can be subdivided into three subtypes:
macroautophagy, microautophagy, and chaperone-mediated
autophagy (CMA) [10]. Macroautophagy is the most univer-
sal form of autophagy characterized by the formation of
autophagosome and is capable of disposing protein aggregates
and damaged organelles [11, 12]. On the other hand,
microautophagy is a lesser known self-eating event [13].
During the microautophagic process, cytosolic components
are transported into the lysosome by direct invagination of
lysosomal membrane and subsequent budding of vesicle into
the lysosomal lumen [14]. In contrast, CMA is a unique
pathway by which cytosolic protein aggregates are selectively
transferred into lysosome for degradation [15]. Neither vesicle
formation nor major changes in the lysosomal membrane
occur during the CMA process [16]. Intriguingly, mounting
evidences demonstrated that there is a functional relationship
between macroautophagy and CMA, in particular, in the
setting of neurological diseases [17, 18]. Dysfunction of either
one of them can lead to a compensatory upregulation of the
other. In this review, we aim to provide an integrative over-
view that concentrates on the interaction between
macroautophagy and CMA in the mammalian systems (unless
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otherwise stated), and emphasize further details of the molec-
ular mechanisms underlying the crosstalk between
macroautophagy and CMA. Lastly, we will discuss therapeu-
tic potentials by targeting macroautophagy-CMA crosstalk in
the treatment of neurological diseases.
Macroautophagy and CMA: Different Paths
for Intracellular Protein Turnover and Recycling
Macroautophagy: Process and Regulation
The macroautophagic degradation of long-lived proteins and
damaged/superfluous organelles consists of specific steps
(Fig. 1) [19, 20]. It begins with nucleation of a unique mem-
brane structure coined as phagophore, which is followed by
the sequestration of cytoplasmic constituent into the
phagophore. The elongation and closure of phagophore lead
to generation of a double-membrane-bound autophagosome
[21]. Autophagosome can fuse with lysosome to form
autolysosome, where luminal contents of the autophagosome
as well as inner membrane of the autophagic vacuole are
broken down by lysosomal hydrolases [22]. The resultant
biomolecules, such as amino acids, sugars, and lipids, are
transported back into the cytosol for reuse via permeases
functioning [23].
It is important to note that autophagy-related (Atg) proteins
play an important role in autophagosome formation and
macroautopahgy regulation [24–26]. For instance, the ULK1
complex, which consists of ULK1, Atg13, Atg101, and
FIP200 (focal adhesion kinase family-interacting protein of
200 kD), is a vital complex in integrating incoming autophagy
signals to initiate autophagosome biogenesis [27–29]. Beclin
1, the mammalian ortholog of yeast Atg6, can collaborate with
other key subunits such as barkor (Beclin 1-associated
autophagy-related key regulator), p150, and UVRAG (UV
irradiation resistance-associated gene) to form the class III
phosphatidylinositol 3-kinase (PI3K) complex that is crucial
for nucleation and assembly of the initial phagophore mem-
brane [30–33]. The elongation of pre-autophagosomal struc-
tures requires two ubiquitin-like modification systems, includ-
ing Atg12-Atg5-Atg16L (Atg16-like protein) complex and
LC3 (microtubule-associated protein 1 light chain 3) conju-
gation system [34–36]. In the first of these two ubiquitin-like
conjugation reactions, the ubiquitin-like protein Atg12 is co-
valently tagged to Atg5 with the help of E1-like ubiquitin
activating enzyme Atg7 and E2-like ubiquitin conjugating
enzyme Atg10 [37–39]. The Atg12-Atg5 conjugate can then
interact non-covalently with ATG16L to form the Atg12-
Atg5-Atg16L tetramers, which function as a E3-like ubiquitin
ligase that contributes to expansion of autophagosomal mem-
brane by promoting LC3 lipidation [40, 41]. In the second
ubiquitin-like conjugation reaction, LC3 is conjugated to
phosphatidylethanolamine (PE) by E1-like Atg7 and E2-like
Atg3 to form LC3-II [42, 43]. LC3-II can be specifically
targeted to the elongating membrane, which aids the closure
of autophagosomal membrane to form an autophagosome
[44].
Multiple upstream signals, including mammalian target of
rapamycin (mTOR)-dependent and -independent pathway,
can regulate the process of macroautophagy [45, 46]. The
serine/threonine protein kinase mTOR serves as a primary
negative regulator of macroautophagy, and inactivation of
mTOR promotes the macroautophagic process [47]. On the
other hand, signaling pathways, such as cAMP-Epac-PLC-ε-
IP3 pathway and Ca2+-calpain-G-stimulatory protein α path-
way, can modulate macroautophagic response in an mTOR-
independent manner [46, 48]. A more detailed regulatory
mechanism of macroautophagy has been extensively de-
scribed elsewhere [49–51].
CMA: Process and Regulation
CMA is another subset of autophagy that has only been
described in mammalian cells, and it is distinct from
macroautophagy due to its specific mechanism of cargo se-
lection and delivery to the lysosomal lumen for disposal [52].
In this form of autophagy, protein structures are selectively
delivered into lysosome individually. Heat shock cognate
chaperone of 70 kDa (hsc70) plays an important role in the
CMA pathway (Fig. 1) [53]. Hsc70, together with its co-
chaperones (e.g., hsc90), recognizes a specific consensus pen-
tapeptide motif KFERQ in all cytosolic proteins targeting for
CMA by forming a chaperone/substrate complex [54].
Initially, the chaperone/substrate complex is associated with
lysosomal membrane protein receptor LAMP-2A (lysosome-
associated membrane protein type 2A) [55]. The substrate
protein can then be transported into lysosomal lumen for
degradation with assistance of lysosomal-hsc70 (lys-hsc70)
[56, 57].
The activity of CMA can be modulated by regulating local
levels of LAMP-2A and lys-hsc70 at the lysosomal compart-
ment [54]. Inhibition of p38 mitogen activated protein kinase
(MAPK) can partially suppress the activation of CMA, sug-
gesting the involvement of this signaling pathway in the
modulation of CMA [58]. However, more signaling pathways
which participate in the regulation of CMA remain to be
clarified.
Macroautophagy and CMA in Neurological Disorders
The autophagic-lysosomal systems, both macroautophagy
and CMA, are important for cellular quality control to protect
neurons from many kinds of damage and disease, such as
acute injury, chronic neurodegeneration, and brain tumors.
For instance, macroautophagy provides neuroprotective
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effects against ischemic, hemorrhagic, and traumatic brain
injury [59–61]. Proper functioning of macroautophagy con-
tributes to prevention of neurodegeneration via clearance of
cytoplasmic aggregate-prone proteins and inclusions [62–64].
To date, the toxicity of causative gene products has been
linked to the development of certain neurodegenerative disor-
der. Missense mutations in the amyloid precursor protein
(APP) and presenilin genes can lead to an increase in the
production of the amyloid-beta (Aβ) peptide, which can pre-
dispose to the development of AD-type brain pathology
[65–69]. Pathogenic mutations in the tau gene can lead to
abnormality in the function or isoform composition of this
microtubule-associated protein, which contributes to the for-
mation of abundant neurofibrillary lesions in AD and other
tauopathies [70–73]. Stimulation of macroautophagy en-
hances the clearance of Aβ peptide and the APP-derived
fragment in neurons and provides protective effects in cellular
and animal models of AD [74–76]. Activation of
macroautophagy can also eliminate both soluble mutant tau
protein and its aggregates from the cytoplasm to promote
neuronal survival in cellular and animal tauopathy models
[77, 78]. PD is characterized by formation of neuronal intra-
cellular Lewy body inclusions and the loss of dopaminergic
neurons from the substantia nigra. Mutations in the α-
synuclein gene (such as A53T and A30P) and the parkin gene
are genetically linked to familial forms of PD [79–81]. In
addition, mutations in the leucine-rich repeat kinase 2 gene
(LRRK2) are clinically linked to PD [82–84]. These mutated
gene products work together to promote the abnormal protein
aggregation and Lewy body formation in PD [85–88]. More
importantly, macroautophagy serves as a route for intracellular
α-synuclein degradation to ameliorate the neurodegenerative
pathology in PD models [89, 90]. In HD, an expansion of a
CAG trinucleotide repeat in the interesting transcript 15 gene
results to a mutant huntingtin protein with an abnormally
expanded polyglutamine tract [91]. This cytotoxic
polyglutamine-expanded huntingtin protein is highly
expressed in neurons of the brain and can lead to the hallmark
pathology of HD [92, 93]. Macroautophagy functions as a key
clearance pathway for mutant huntingtin fragments that re-
duces intracellular huntingtin accumulation and protects cells
against polyglutamine toxicity in HD models [45, 94, 63].
Similarly, activation of macroautophagy is beneficial for other
so-called polyglutamine diseases, and it contributes to the
degradation of mutant ataxin-3 protein that causes
spinocerebellar ataxia type 3 [95–97]. Additionally, the mu-
tant superoxide dismutase (SOD1) proteins, which are linked
to familial amyotrophic lateral sclerosis, can be degraded by
macroautophagy [98–100]. The impairment of the
macroautophagy pathway is a crucial pathogenic mechanism
Fig. 1 The cellular events of macroautophagy and CMA
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of hereditary spastic paraplegia [101, 102]. Whereas,
macroautophagy serves as a pro-death mechanism for brain
tumor cells under certain conditions [103, 104]. Treatment
with cytotoxic drugs such as arsenic trioxide and selenite
triggers mitochondrial damage and initiates autophagic cell
death in malignant glioma cells [103, 104].
Likewise, the signaling pathway of CMA is activated dur-
ing hypoxic and ischemic stress to promote neuronal cell
survival under these conditions [105]. Dysfunction of CMA
causes accumulation of abnormal proteins in the pathological
brain, which is involved in the pathogenesis of chronic neu-
rodegeneration, such as PD [106], AD [107], and HD [108].
Indeed, the pathophysiological roles of CMA in the removal
of aggregate-prone proteins that cause neurodegenerative dis-
eases are being investigated. Evidence from both in vitro and
in vivo studies supports that α-synuclein is a bona fide CMA
substrate [109–111]. Wild-type α-synuclein, which contains a
CMA-targeting motif in its sequences, can be delivered to
lysosomes for its degradation via the CMA pathway [109].
Whereas, the pathogenic mutants of α-synuclein can bind to
the CMA receptor LAMP-2A but fail to translocate inside the
lysosomal lumen, thus impairing their own degradation along
with that of other CMA substrates through this pathway [112].
Also, dopamine-modified α-synuclein can be bound to the
lysosomal membrane, but it fails to translocate into lyso-
somes, resulting in the blockage of its degradation by CMA
[113]. In the postmortem study of seven brain samples from
PD patients, Alvarez-Erviti et al. reported a reduced expres-
sion of CMA proteins LAMP-2A and hsc70 in the substantia
nigra pars compacta and amygdala of PD brains [114].
Downregulation of CMA activity compromises the degrada-
tion of alpha-synuclein, which underpins the Lewy body
formation and PD pathogenesis [109, 115, 116].
Overexpression of LAMP-2A restores CMA activity and
reduces the levels of aberrant α-synuclein and thereby ame-
liorates α-synuclein-induced dopaminergic neurodegenera-
tion [106]. Although proteins like huntingtin contain CMA-
targeting motifs in their sequences, the amount of these wild-
type proteins degraded by CMA is negligible under normal
conditions [117, 118]. However, in the case of HD, mutant
huntingtin is selectively degraded by CMA through an hsc70
and LAMP-2A-dependent manner [108, 119]. Thus, function-
al regulation of this autophagy-lysosomal pathway provides
novel means to prevent these devastating cerebral disorders.
Crosstalk Between Macroautophagy and CMA: a Potential
Target for the Treatment of Neurological Diseases
Under normal cellular settings, macroautophagy and CMA
occur at a basal level, but they can be activated when cells
encounter stressful stimuli [54, 120]. During nutrient depriva-
tion, the activity of macroautophagy rapidly upregulates and
reaches the maximum level around 4∼6 h postfasting but
downregulates immediately thereafter [121]. If the nutritional
stress continues, the CMA pathway will be enhanced. The
pathway activity peaks at 12∼20 h and remains to be active in
the long-term starvation [122]. Increasing evidence has indi-
cated that macroautophagy and CMA directly communicate
with each other in protein degradation to maintaining cell
homeostasis (Fig. 2) [123, 124]. For instance, in a cell model
of tauopathy expressing TauRD△K280, Wang and colleagues
proposed that the inability of complete degradation of mutated
tau protein by the CMA pathway can lead to the pro-
aggregating substrate generation and tau aggregation,
resulting in tau pathology. At the same time, macroautophagy
is able to clear these CMA-related tau aggregates, suggesting
the functional interrelationships betweenmacroautophagy and
CMA [125, 117]. With series of key findings, molecular
mechan i sms unde r ly ing the c ros s t a lk be tween
macroautophagy and CMA are beginning to be elucidated.
Dissecting these interactions between macroautophagy and
CMA is essential for characterizing their respective roles in
physiological and pathological conditions.
CMA-Blockage-Induced Macroautophagy Upregulation
CMA is a cargo-specific subtype of autophagy which dictates
multiple physiological functions [126]. It contributes to amino
acid recycling during prolonged starvation [122] and fulfills
protein quality control functions via selective turnover of
damaged or malfunctioning proteins from the cytosol [127,
128]. As mentioned above, malfunction of CMA is implicated
in the pathogenesis of cerebral diseases. In PD, the pathogenic
A53T and A30P α-synuclein mutants can strongly bind to the
CMA receptor LAMP-2A on lysosomes. However, these
mutant forms of α-synuclein cannot be translocated into the
lysosomal lumen, which inhibits not only the lysosomal up-
take of their own but also that of other substrates for CMA
degradation [109]. More importantly, in the PC12 cell model,
pathogenic α-synuclein-mutant-mediated blockage of CMA
leads to compensatory activation of macroautophagy, which
makes up for portions of CMA’s functions in protein degra-
dation [109]. In the cortical neurons and differentiated SH-
SY5Y cells, the dysfunction of CMA conferred by mutant
A53T α-synuclein can also result in an increased activity of
macroautophagy [112]. However, under this condition, the
compensatory upregulation of macroautophagy secondary to
CMA inhibition due to overexpression of mutant A53T α-
synuclein does not contribute to an increase of
macroautophagy-dependent degradation. Instead, it causes
the accumulation of autophagosomes that leads to membrane
destabilization of these autophagic vacuoles and the cytoplas-
mic release of vacuolar hydrolases, thus eventually inducing
autophagic cell death of primary cortical neurons [112, 129,
130]. The molecular mechanism underlying such a compen-
satory response of macroautophagy owing to CMA
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impairment, however, is still unclear. It has been demonstrated
that in the early stage after CMA blockage by RNA interfer-
ence against the lysosomal membrane receptor, LAMP-2A, its
macroautophagic activity decreases because of an increase in
mTOR activity. However, as CMA blockage persists, the
increased intracellular levels of Beclin 1, along with the re-
duced phosphorylation of mTOR, can work together to induce
constitutive activation of the macroautophagy[131].
Under basal conditions, compensatory macroautophagy is
able to help CMA-defective cell to maintain normal protein
degradation and cell viability [17]. However, upon exposure
to certain stressors, such as pro-oxidative and oxidative stim-
uli (i.e., cadmium, paraquat, and H2O2), or to UV light, CMA-
defective cell undergoes more apoptotic cell death. This sug-
gests that despite the constitutive upregulation of
macroautophagy, it is unable to compensate for all CMA
functions [17]. It is proposed that the persistent activation of
this pathway due to CMA blockage could lead to continuous
consumption of the macroautophagic machinery proteins in
chronically CMA-impaired cells and thus may limit a major
increase in the activity of this pathway to respond to stress
[131]. Therefore, in future research, it would be important to
investigate whether constitutive activation of macroautophagy
can always lead to the failure of its inducible form in response
to stress, and to identify the time frame needed for this switch
[131]. Additionally, considering the fact that aberrant
Fig. 2 Schematic illustrating the interrelations between macroautophagy
and CMA. Macroautophagy and CMA communicate with each other in
the process of autophagy-lysosomal degradation. CMA blockage can
induce compensative upregulation of macroautophagy, and the CMA
pathway compensates when macroautophagy is inhibited. Molecular
directors such as hsc70, Nrf2, ubiquilin, and p53 may function as core
network nodes in macroautophagy-CMA crosstalk
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activation of macroautophagy secondary to CMA inhibition
leads to autophagic cell death of cortical neurons, improving
the function of CMA function is important because it can
mitigate potential deleterious consequences of aberrant induc-
tion of macroautophagy in this specific context ofα-synuclein
overexpression [112].
CMA Compensates When Macroautophagy Is Inhibited
Macroautophagy is the bulk protein degradation pathway that
plays an important role in protein quality control and main-
taining cellular homeostasis of neural cells [8, 62]. A failure of
macroautophagy-mediated clearance of misfolded proteins
will cause the accumulation of these toxic proteins inside the
affected neurons, leading to neurodegenerative disorders
[132–134]. In the case of HD, activation of the kinase activity
of inositol-requiring enzyme 1 mediates endoplasmic reticu-
lum stress–induced inhibition of macroautophagic flux that
causes accumulation of mutant huntingtin aggregates in cells,
thus resulting in neuronal cell death [135, 136]. Martinez-
Vicente et al. found that a defect in the ability of autophagic
cargo recognition by autophagosomes compromises the re-
moval of cytosolic components. As a result, there are in-
creased levels of protein aggregates and abnormal intracellular
lipid stores as well as a persistent level of dysfunctional
mitochondria in HD cells [137]. Intriguingly, the impairment
of macroautophagy can lead to activation of the CMA path-
way under both basal and stress conditions [124]. An increase
in the number of CMA translocation components (including
LAMP-2A and hsc70) and CMA-competent lysosomes helps
to boost the CMA activity following macroautophagy inhibi-
tion [124]. In cellular and mouse models, the HD cells are able
to upregulate the activity of CMA pathway by increasing the
de novo synthesis of LAMP-2A proteins and stabilizing of
LAMP-2A at the lysosomal membrane followed by the block-
age of macroautophagy in these cells [138]. It is proposed that
cells obey different mechanisms to mediate the compensatory
activation of CMA to respond to macroautophagy blockage
depending on different conditions [127, 139]. The de novo
synthesis of the receptor protein would be a major way to
increase levels of LAMP-2A under basal conditions. In con-
trast, changes in the LAMP-2A protein already in the lyso-
somal compartment (i.e., reduced breakdown of LAMP-2A
protein already at the lysosomal membrane) could be more
optimal than de novo synthesis of this protein under stress
conditions [124]. Therefore, it is interesting to determine
whether or not there exist different mechanisms underlying
compensatory upregulation of CMA secondary to
macroautophagy blockage.
The compensative upregulation of CMA in response to
macroautophagy inhibition promotes removal of oxidized
proteins, which protects Atg5−/−murine embryonic fibroblasts
from oxidative-stress-mediated cell death [140, 141]. Also,
evidences from an in vivo study demonstrated that a compen-
satory CMA due to compromised macroautophagy provides a
protective effect that contributes to the function preservation
of cone retinal cells in conditional Atg5 knockout in mice
[142]. Notably, different with the evidence from Atg5 null
mouse embryonic fibroblasts [141], enhancement of CMA
pathway secondary to macroautophagy inhibition fails to pre-
vent RALA hepatocytes from menadione-induced oxidative
stress and cell death [143]. These data suggest that
macroautophagy and CMA have non-redundant functions in
hepatocyte to resist to oxidant stress.
Taken together, macroautophagy is able to degrade the
CMA substrates; however, it cannot compensate for selective
degradation of particular substrates by CMA. Comparatively,
CMA is capable of degrading cytosolic proteins but fails to
take care of macroautophagy-mediated degradation of expired
organelles. Despite these limitations, compensatory upregula-
tion of one of them is beneficial for cells when the other is
compromised, which helps cells to resist various types of
damage to maintain cell viability [17, 141].
Crosstalk Between Autophagy and Ubiquitin-Proteasome
System (UPS)
The UPS is a major selective protein degradation pathway that
plays important roles for eukaryotic cells [144]. UPS targets
biologically non-useful proteins such as mutant, misfolded,
damaged, or otherwise abnormal proteins for rapid substrate-
specific proteolysis. In the CNS, UPS modulates a variety of
basic cellular processes of neurons such as neuronal growth
and development, synaptic function and plasticity, and neuro-
nal survival and homeostasis [145]. Defect of the UPS has
been linked to the pathogenesis of neurological disorders
[146–148].
It is noteworthy that UPS and the autophagy-lysosomal
system are functionally coupled in degrading excess or dam-
aged proteins to maintain cellular homeostasis and neuronal
survival [149, 150]. In a fly model of spinobulbar muscular
atrophy, macroautophagy compensates for impaired UPS
function in a histone deacetylase 6 (HDAC6)-dependent man-
ner [151]. The compensatory macroautophagy due to protea-
some inhibition plays an important role in controlling endo-
plasmic reticulum stress and reducing cell death [152, 153].
Also, in response to macroautophagy inhibition, proteasomes
are activated in a compensatory manner for protein degrada-
tion [154]. Moreover, CMA and UPS collaborate to degrade
the gene product of regulator of calcineurin 1, whose overex-
pression has been linked to Down syndrome (DS) and AD
neuropathology [107]. Thus, further efforts are anticipated to
explore the functional relationships between UPS and autoph-
agy with the goal of controlling these interactions for optimiz-
ing the therapeutic approaches for cerebral diseases.
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Future Direction
Macroautophagy and CMA communicate with each other
extensively in the autophagy-lysosomal degradation process.
In certain circumstances, one can serve as a backup mecha-
nism when the other is defective, and vice versa. However,
research in the crosstalk between macroautophagy and CMA
is still in its infancy. Better knowledge of the compensatory
mechanisms between these two autophagic pathways, their
advantages, and their limitations is of great significance, in
order to develop effective interventions to regulate them for
therapeutic purposes in autophagy-associated human
disorders.
In particular, elucidation of the interrelationships between
macroautophagy and CMAwould have great clinical signifi-
cance for intervention of those devastating cerebral disorders.
As described above, macroautophagy and CMA are intercon-
nected during protein degradation process in neurons. When
either one is compromised, cells initiate the other autophagic
pathway in a compensatory manner. However, inappropriate
or excessive compensatory activation of autophagy may lead
to neuronal cell death in the pathophysiological process of
cerebral disorders. In addition, compensatory activation of the
autophagic pathway may promote the development of brain
tumors and its resistance to anticancer therapy [155–157].
Therefore, exploring the crosstalk between these two subtypes
of autophagy helps to further define their exact roles in brain
pathology (i.e., if they are the primary causes or the secondary
consequences of pathological alterations). As a result, this will
allow further molecular insights into the progressive dysfunc-
tion of autophagic protein degradation that leads to neurolog-
ical diseases. It also provides key information for better ma-
nipulation of macroautophagy and CMA in the treatment and
prevention of cerebral disorders.
Therefore, a series of critical issues regarding the
macroautophagy-CMA network are warranted to be ad-
dressed. First, the physiological and pathological roles of
macroautophagy and CMA require further investigation
[126]. To date, little is known about the regulation of basal
macroautophagy and CMAunder normal conditions.Whether
they function as a pro-death or pro-survival program in certain
cerebral disorders should be addressed. Second, although
there is evidence of inter rela t ionships between
macroautophagy and CMA [158], the temporal associations,
the universality, the functional consequences, and the molec-
ular directors of the macroautophagy-CMA chat are less un-
derstood. It is worthy to note that regulation of the levels of
hsc70 in the lysosomal lumen during macroautophagy block-
age offers clues about possible molecular mechanisms behind
the crosstalk between these two autophagic pathways [124].
In macroautophagy-deficient cells, reduced fusion of
autophagosomes with lysosomes could result in less dissipa-
tion of lysosomal pH. This causes more acidic environment in
these lysosomes [124]. Lower lysosomal pH confers more
stability of hsc70 in the lysosomal lumen to mediate CMA
[124]. Recently, Rothenberg et al. demonstrated that ubiquilin
proteins can be consumed by both macroautophagy and CMA
[159]. Ubiquilin can positively regulate macroautophagy by
promoting the conversion of LC3-I to LC3-II and accelerating
autophagosome maturation [160]. However, it is actively de-
graded after carrying out its function during macroautophagic
process. Moreover, ubiquilin contains two pentapeptide se-
quences (ILKDQ and EVRFQ) known as the CMA-targeting
motif, which enable its selective recognition and degradation
by CMA [159]. This dual mode of consumption of ubiquilin
may have important implications in the crosstalk between
macroautophagy and CMA. Therefore, it will be of interest
to discover how ubiquilin is selected for either of these two
forms of autophagy [159]. p53, the “guardian of the cellular
genome” functions in the pathophysiology of cerebral dis-
eases [161–163] , may play a role in mediat ing
macroautophagy-CMA crosstalk. On one hand, p53 can either
promote or inhibit macroautophagy, depending on its subcel-
lular locations [164–166]. On the other hand, inhibition of
macroautophagy results in increased cytosolic levels of mu-
tant p53 proteins in non-proliferating confluent cancer cells.
This allows hsc70 to recognize their KFERQ-like sequence
motifs and in turn enhances the degradation of mutant p53 in a
CMA-dependent manner [18]. Additionally, the Nrf2 pathway
could serve as an upstream signal to regulate the activities of
both macroautophagy and CMA [167]. Genetical increase of
astrocyte-specific Nrf2 can attenuate the functional deficiency
of macroautophagy and CMA, which promotes the
autophagy-lysosomal degradation of human mutant α-
synuclein in the α-synuclein mutant mouse model [167].
Future investigations should focus more on key molecules
such as ubiquilin, p53, and Nrf2, which might act as a core
network node in the crosstalk between macroautophagy and
CMA. Finally, large-scale proteomic- and metabolomic-based
studies, as well as transgenic-based approaches, should pro-
vide valuable clues on the matter of macroautophagy-CMA
crosstalk.
Concluding Remarks
Macroautophagy and CMA exert critical roles in maintaining
neuronal homeostasis in the brain under physiological and
pathological conditions. Although considerable advances
have been made in our insights into the macroautophagy-
CMA network, key aspects regarding the interplay of these
two catabolic pathways, including the compensatory mecha-
nisms and their benefits and limitations, remain enigmatic.
Answers to these questions are particularly significant to
allow better manipulation of these two important autophagy-
1290 Mol Neurobiol (2015) 52:1284–1296
lysosomal pathways in the treatment of autophagy-related
cerebral diseases.
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